Companies
Abbott
dominating the massive POC and continuous glucose monitoring (CGM) consumer markets.
- Country
- United States
- Ticker
- ABT
point-of-care
us
legacy
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Abbott funded the $20.6 billion acquisition of Exact Sciences primarily through the issuance of $20.0 billion of long-term debt in March 2026, with the remainder from cash on hand. | sec.gov |
| Capacity | Abbott operates 89 manufacturing facilities globally, which are deemed suitable and provide adequate productive capacity. | sec.gov |
| Certification | Abbott's laboratories and associated testing services are subject to registration, certification, and licensure by federal, state, and local agencies. | sec.gov |
| Regulatory approval | Abbott's products are subject to rigorous regulatory approvals by the FDA and other national and international authorities. Recent approvals include the Volt PFA System (US, 2025) and Libre Duo (US, 2026). | prnewswire.com · sec.gov |
| Production site | Abbott operates 89 manufacturing facilities globally, including 33 in the Medical Devices segment and over 30 locations in the US. Specific sites include facilities in Lake Forest, Illinois; Temecula, California; Sylmar, California; and Kilkenny, Ireland. | markitfeed.com · sec.gov |
| Headcount | As of December 31, 2025, Abbott employed approximately 115,000 people. | sec.gov |
| Revenue | Abbott's total reported revenue for the full year 2025 was $44.328 billion. | prnewswire.com |
Independent sources: markitfeed.com · prnewswire.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Diagnostics & biosensors | diagnostics-medtech | Low | → |
| Point-of-care molecular diagnostics | diagnostics-medtech | Low | → |
| Wearable biodiagnostics | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.